Norges Bank Prometheus Biosciences, Inc. Transaction History

Norges Bank

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.0 - $199.92 $0 - $97.7 Million	-488,745 Closed	0 $0
Q1 2023 May 15, 2024	BUY	$103.46 - $126.29 $15.9 Million - $19.4 Million	153,492 New	153,492 $16.5 Million
Q4 2022 Feb 14, 2023	BUY	$36.06 - $117.21 $2.25 Million - $7.33 Million	62,500 New	62,500 $6.88 Million
Q2 2022 Aug 14, 2023	BUY	$22.39 - $38.94 $10.9 Million - $19 Million	488,745 New	488,745 $13.8 Million
Q1 2022 May 12, 2023	BUY	$30.13 - $50.0 $24.9 Million - $41.3 Million	825,489 Added 1320.78%	887,989 $33.5 Million
Q1 2022 May 09, 2022	SELL	$30.13 - $50.0 $18.2 Million - $30.3 Million	-605,444 Closed	0 $0
Q4 2021 Mar 09, 2022	BUY	$22.28 - $39.54 $13.5 Million - $23.9 Million	605,444 New	605,444 $23.9 Million
Q3 2021 Nov 14, 2022	BUY	$20.89 - $26.96 $8.19 Million - $10.6 Million	391,952 New	391,952 $9.29 Million
Q3 2021 Nov 05, 2021	SELL	$20.89 - $26.96 $8.19 Million - $10.6 Million	-391,952 Closed	0 $0
Q2 2021 Aug 15, 2022	BUY	$16.8 - $29.65 $6.58 Million - $11.6 Million	391,952 New	391,952 $9.63 Million
Q2 2021 Aug 10, 2021	SELL	$16.8 - $29.65 $6.58 Million - $11.6 Million	-391,952 Closed	0 $0
Q1 2021 May 09, 2022	BUY	$16.51 - $25.29 $6.47 Million - $9.91 Million	391,952 New	391,952 $7.16 Million

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.